CME/CE

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU Guest: Amy Mottl, MD, MPH Guest: Muthiah Vaduganathan, MD, MPH This three-part panel series explores how emerging evidence from the CONFIDENCE trial is shaping the future of cardio-kidney-metabolic (CKM) care. In Chapter 1, the experts discuss the additive benefits and safety of combining a nonsteroidal MRA and an SGLT2 inhibitor. Chapter 2 focuses on pat...

Guest: Reshma L. Mahtani, DO In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants will gain insights into optimal evidence-based treatment...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Robert J. Motzer, MD Guest: Elizabeth R. Plimack, MD, MS, FASCO Our experts, Drs. Robert Motzer and Elizabeth Plimack , discuss first-line treatment strategies for advanced renal cell carcinoma in a community clinic setting. Drawing from pivotal clinical trials and guideline recommendations, the y highlight how to personalize therapy based on IMDC risk stratification and patient characteris...

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.